Dr. Deepthi Vodnala, MD

Dr. Vodnala practices at Saint Luke's Hospital of Kansas City in Kansas City, Missouri, part of BJC Health.

Dr. Vodnala's NPI, 1699903690, was assigned on June 29, 2009. Dr. Vodnala holds Missouri license 2015009833.

Dr. Vodnala's primary practice is Saint Luke's Hospital of Kansas City, at 4401 Wornall Road, Kansas City, MO 64111 in Jackson County. The practice phone is (816) 932-2000.

Dr. Vodnala's primary practice is Saint Luke's Hospital of Kansas City in Kansas City, Missouri, part of BJC Health. Dr. Vodnala is also affiliated with Saint Luke's North Hospital-Barry Road. The medical group on file is Saint Luke's Medical Group. Dmand AI also links Dr. Vodnala to 3 more hospitals, 2 medical groups, 1 group practice or clinic, 1 home health agency and 1 therapy and rehab clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Vodnala practices, 8 sites in all. Vendor and product names are available with a free account.

Advanced heart failure and transplant cardiology is Dr. Vodnala's primary specialty in the NPI Registry, under taxonomy code 207RA0001X. Dmand AI has Dr. Vodnala's licenses on file in 3 states: Missouri, Kansas and Michigan.

CMS data shows 2,648 Medicare services from Dr. Vodnala across 24 procedure codes in 2024, for 1,576 Medicare patients. Medicare paid $105,926 for them.

CMS counts 1,576 Medicare patients who saw Dr. Vodnala in 2024. The largest group is 75 to 84, with 613 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.82, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Vodnala's median patient age at 73, with 47% women.

In 2024, Dr. Vodnala wrote 6,324 Medicare Part D claims for 824 patients. 80% of them were for generic drugs. CMS names the drug for 5,974 of them, across 72 drugs with 11 or more claims each, at $1,311,673 in total drug cost. In 2023, CMS named 5,040 claims across 66 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Vodnala for performance year 2024, reported as part of a group. Dr. Vodnala accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Vodnala as offering telehealth.

Dmand AI links 11 papers to Dr. Vodnala, published from 2011 to 2021. 2011 was the busiest year, with 3. The most frequent topics are Heart Transplantation and Heart Failure. Dr. Vodnala has published most often in J Card Fail. Dr. Vodnala's most frequent co-authors are Robert D. Brook, MD, Bethany A. Austin, MD and A. Michael Borkon, MD.

Dmand AI links Dr. Vodnala to 1 clinical trial.

CMS Open Payments shows 17 general payments to Dr. Vodnala from 3 drug and device companies from 2016 to 2025. Compensation for serving as faculty or as a speaker for a medical education program make up the largest share, 70% of the total. Abbott Laboratories paid the most, $2,699.